Seller record · telehealth service · struthealth.com
Strut Health
A telehealth service selling compounded GLP-1 drugs, peptides and men's health medications. An FDA warning letter names the operating entity.
Passes 6 of 8 criteria. Recorded against Standard v1.1, August 2026.
Operating entity Strut Health, LLC
Dispositions at a glance
| Code | Criterion | Disposition |
|---|---|---|
| S1 | Prescriber requirement | PASS |
| S2 | Prescription gating | PASS |
| S3 | Pharmacy identification | FAIL |
| S4 | Compounding disclosure | PASS |
| S5 | Analytical documentation | FAIL |
| S6 | Business address | PASS |
| S7 | Price disclosure | PASS |
| S8 | Enforcement status | PASS |
Evidence, criterion by criterion
What was read, where, and on what date, for each disposition in the table above.
S1PASSA licensed United States physician reviews the profile and prescribes if clinically appropriate; the founder is named as Simal Patel, MD.Source: struthealth.com/how-it-works · read August 2026.
S2PASSThe order path was walked from the semaglutide page and stopped at the medical questions introduction inside checkout.Source: struthealth.com/checkout/medical-questions/intro · read August 2026.
S3FAILMedication is said to come from a licensed United States pharmacy, and no filling facility is named on any page read.Source: struthealth.com/our-story · read August 2026.
S4PASSCompound prescription products have not been tested or approved by the FDA, printed on the semaglutide product page.Source: struthealth.com/weight-loss/semaglutide · read August 2026.
S5FAILNo certificate, lot report or test document appears on the product page, the FAQ, or in the published sitemap.Source: struthealth.com/sitemap.xml · read August 2026.
S6PASS701 Commerce St, Dallas, Texas 75202, printed in the footer and matching the address on the warning letter.Source: struthealth.com · read August 2026.
S7PASSInjectable semaglutide at 129 dollars for a monthly vial, and oral semaglutide at 199 dollars for a thirty-day supply.Source: struthealth.com/weight-loss/semaglutide · read August 2026.
S8PASSFDA warning letter 721448, February 2026, names Strut Health, LLC dba Strut at 701 Commerce St, Dallas, Texas, alleging that claims about its compounded semaglutide and tirzepatide products, including the representation that Strut is the compounder, are false or misleading. No close-out letter appears in the index. No FDA action has halted the business, and the storefront still trades.Source: fda.gov, letter 721448 · read August 2026.
Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sermorelin, NAD+, enclomiphene, tadalafil, tretinoin, minoxidil.
Dispositions recorded against Standard v1.1, August 2026. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.